Olema Pharmaceuticals, Inc. $OLMA Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 11.4% in the 4th quarter, Holdings Channel reports. The firm owned 3,561,355 shares of the company’s stock after purchasing an additional 364,035 shares during the period. Vanguard Group Inc. owned about 0.05% of Olema Pharmaceuticals worth $89,034,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new position in shares of Olema Pharmaceuticals in the first quarter worth $172,000. Goldman Sachs Group Inc. grew its stake in shares of Olema Pharmaceuticals by 93.6% in the first quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after acquiring an additional 358,412 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Olema Pharmaceuticals by 216.8% in the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock worth $521,000 after acquiring an additional 94,815 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Olema Pharmaceuticals by 22.4% in the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after acquiring an additional 242,997 shares in the last quarter. Finally, Creative Planning acquired a new position in shares of Olema Pharmaceuticals in the second quarter worth $83,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on OLMA. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Wolfe Research began coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They issued a “peer perform” rating for the company. Citigroup boosted their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Finally, Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.10.

Insider Activity

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $13.58 on Thursday. The stock has a market cap of $1.19 billion, a P/E ratio of -6.72 and a beta of 2.05. The company has a fifty day simple moving average of $15.79 and a 200-day simple moving average of $20.45. Olema Pharmaceuticals, Inc. has a 12-month low of $3.89 and a 12-month high of $36.26. The company has a current ratio of 9.95, a quick ratio of 9.95 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). Equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.